Articles with "peg rhg" as a keyword



Photo by kellysikkema from unsplash

A multicenter phase II trial of primary prophylactic PEG-rhG-CSF in pediatric patients with solid tumors and non-Hodgkin lymphoma after chemotherapy: An interim analysis.

Sign Up to like & get
recommendations!
Published in 2023 at "Cancer medicine"

DOI: 10.1002/cam4.6079

Abstract: BACKGROUND Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can be used in pediatric patients. This study assessed the safety and efficacy of PEG-rhG-CSF as a primary prophylactic drug against neutropenia after chemotherapy in pediatric patients… read more here.

Keywords: peg rhg; pediatric patients; rhg csf;
Photo from wikipedia

Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony‐Stimulating Factor in Healthy Chinese Subjects: An Open‐Label, Randomized, Parallel‐Design Bioavailability Study

Sign Up to like & get
recommendations!
Published in 2020 at "Clinical Pharmacology in Drug Development"

DOI: 10.1002/cpdd.819

Abstract: Pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF, pegfilgrastim) is a long‐acting derivative of recombinant human granulocyte colony‐stimulating factor with limited renal clearance and a longer half‐life. It is used for the prevention of febrile neutropenia,… read more here.

Keywords: recombinant human; treatment; peg rhg; rhg csf ... See more keywords
Photo from wikipedia

Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer

Sign Up to like & get
recommendations!
Published in 2018 at "Cancer Chemotherapy and Pharmacology"

DOI: 10.1007/s00280-018-3639-z

Abstract: PurposeTo explore the efficacy and safety of daily administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF), and a single subcutaneous injection of polyethylene glycol recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF, a sustained-duration rhG-CSF) in neutropenia… read more here.

Keywords: chemotherapy; recombinant human; csf; peg rhg ... See more keywords
Photo by kellysikkema from unsplash

Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study

Sign Up to like & get
recommendations!
Published in 2017 at "Breast Cancer Research and Treatment"

DOI: 10.1007/s10549-017-4609-6

Abstract: BackgroundPEG-rhG-CSF reduces neutropenia and improves chemotherapy safety. In China’s registration trial (CFDA: 2006L01305), we assessed its efficacy and safety against rhG-CSF, and prospectively explored its value over multiple cycles of chemotherapy.MethodsIn this open-label, randomized, multicenter… read more here.

Keywords: incidence; peg rhg; rhg csf; csf ... See more keywords
Photo by paipai90 from unsplash

A prospective, randomized clinical trial of emergency treatment of chemotherapy‐induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF)

Sign Up to like & get
recommendations!
Published in 2022 at "British Journal of Clinical Pharmacology"

DOI: 10.1111/bcp.15507

Abstract: As one of the mainstays of breast cancer therapy, chemotherapy inevitably induces neutropenia. In this study, we explored the role of PEG‐rhG‐CSF (pegylated recombinant human granulocyte colony‐stimulating factor) in the emergency treatment of chemotherapy‐induced grades… read more here.

Keywords: peg rhg; pegylated recombinant; human granulocyte; rhg csf ... See more keywords
Photo by kellysikkema from unsplash

Anaphylaxis caused by pegylated recombinant human granulocyte colony-stimulating factor

Sign Up to like & get
recommendations!
Published in 2022 at "Journal of Oncology Pharmacy Practice"

DOI: 10.1177/10781552221112323

Abstract: Introduction Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF), is commonly used to prevent and/or treat neutropenia caused by tumor chemotherapy and radiotherapy with reduced clearance, increased plasma half-life, sustained biologic activity, and good safety. PEG-rhG-CSF… read more here.

Keywords: peg rhg; anaphylaxis; rhg csf;